De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Lucena-Araujo, Antonio R., Moran, Jason P., VanderLaan, Paul A., Dias-Santagata, Dora, Folch, Erik, Majid, Adnan, Kent, Michael S., Gangadharan, Sidharta P., Rangachari, Deepa, Huberman, Mark S., Kobayashi, Susumu S., Costa, Daniel B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5002311/
https://ncbi.nlm.nih.gov/pubmed/27565908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2016.06.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados